Zevra Therapeutics, Inc. (ZVRA): Net Income
$83.23M
Year ended 2025-12-31
$58.26M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $83.23M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$105.51M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$46.05M | n/m | 2025-03-12, From 2023-01-01 |
| 2022-12-31 | -$26.77M | n/c | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$8.55M | n/m | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | -$12.76M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$24.52M | n/m | 2021-03-12, From 2019-01-01 |
| 2018-12-31 | -$56.47M | n/m | 2020-02-28, From 2018-01-01 |
| 2017-12-31 | -$43.39M | n/m | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | -$16.52M | n/m | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | -$54.66M | n/m | 2018-03-30, From 2015-01-01 |
| 2014-12-31 | -$24.45M | n/m | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | -$5.23M | n/a | 2016-03-16, From 2013-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $83.23M | n/m |
| Zymeworks Inc. (ZYME) | 2025-12-31 | -$81.13M | n/m |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$153.49M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $9.88M | -44.8% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $23.28M | -60.7% |
| Xencor Inc (XNCR) | 2025-12-31 | -$91.92M | n/m |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$784.96M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$38.72M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$74.90M | n/m |
Compare ZVRA, ZYME, URGN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗